Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company operates in Network and Hospital segments. The company's services comprise linear accelerators external beam radiotherapy, gamma knife radiosurgery, head gamma knife systems, body gamma knife systems, and diagnostic imaging services. It also offers other treatments and diagnostic services comprising electroencephalography for the diagnosis of epilepsy; thermotherapy for pain relief after radiotherapy and chemotherapy; ultrasound therapy for the treatment of cancer; stereotactic radiofrequency ablation for the treatment of Parkinson's disease; and refraction and tonometry for the diagnosis of ophthalmic conditions. In addition, the company provides clinical support services, including developing treatment protocols for doctors; and organizing joint diagnosis between doctors in its network and clinical research. Further, it offers radiotherapy and diagnostic equipment leasing and management services to hospitals, as well as tele-consulting services; and sells medical equipment. Additionally, the company establishes the Beijing Proton Medical Center that provides radiotherapy treatment options to cancer patients; and other specialty cancer hospitals, which offer radiotherapy services, diagnostic imaging services, chemotherapy, and surgery. As of June 30, 2019, it operated a network of 30 centers based in 20 hospitals in 20 cities across 13 provinces and administrative regions in China. Concord Medical Services Holdings Limited was incorporated in 2007 and is headquartered in Beijing, the People's Republic of China.
IPO Year: 2009
Exchange: NYSE
Website: concordmedical.com
Date | Price Target | Rating | Analyst |
---|
BEIJING, Sept. 22, 2023 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2023[1]. 2023 First Half Highlights Total net revenues were RMB284.5 million (US$39.2 million) in the first half of 2023, representing a 97.2% increase from total net revenues of RMB144.3 million in the same period last year. Total net rev
BEIJING, Sept. 23, 2022 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2022[1]. 2022 First Half Highlights Total net revenues were RMB144.3 million (US$21.5 million) in the first half of 2022, representing a 25.2% decrease from total net revenues of RMB192.9 million in the same period last year. Total net reve
BEIJING, Dec. 10, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:CCM), a healthcare provider specializing in cancer care, research, and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centers in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2021[1]. 2021 First Half Highlights Total net revenues were RMB192.9 million ($29.9 million) in the first half of 2021, representing a 132.4% increase from total net revenues of RMB83.0 million in the same period last year. Total net revenues included th
SC 13G/A - Concord Medical Services Holdings Ltd (0001472072) (Subject)
BEIJING, Dec. 28, 2020 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centers in China, today announced that the Company has, through its subsidiaries, entered into a definitive agreement to sell 90% equity interest in Concord Healthcare Singapore Pte Ltd, which operates and owns a general medical and surgical hospital, namely Concord International Hospital ("CIH"), for a total consideration of approximately SG$52.2 million. The p
Gainers Venus Concept (NASDAQ:VERO) shares rose 87.9% to $1.1 during Friday's regular session. The company's market cap stands at $7.0 million. Asensus Surgical (AMEX:ASXC) stock moved upwards by 41.22% to $0.33. The market value of their outstanding shares is at $90.3 million. American Oncology Network (NASDAQ:AONC) shares rose 29.41% to $2.2. The market value of their outstanding shares is at $22.4 million. Anebulo Pharmaceuticals (NASDAQ:ANEB) shares rose 29.33% to $2.8. The market value of their outstanding shares is at $72.6 million. IN8bio (NASDAQ:INAB) stock increased by 22.12% to $1.38. The market value of their outstanding shares is at $60.8 million. Geron (NASDAQ:GERN) stock
Gainers Aethlon Medical (NASDAQ:AEMD) shares moved upwards by 124.3% to $0.98 during Thursday's pre-market session. The company's market cap stands at $4.9 million. Virax Biolabs Group (NASDAQ:VRAX) stock increased by 116.82% to $2.32. The company's market cap stands at $5.4 million. iSpecimen (NASDAQ:ISPC) shares increased by 36.65% to $0.44. The market value of their outstanding shares is at $4.3 million. 60 Degrees (NASDAQ:SXTP) shares moved upwards by 28.26% to $0.37. The company's market cap stands at $4.4 million. CERo Therapeutics Hldgs (NASDAQ:CERO) shares rose 27.08% to $1.15. The market value of their outstanding shares is at $17.3 million. OneMedNet (NASDAQ:ONMD) stock incre
Gainers Anitra (AMEX:AZTR) shares increased by 6.5% to $0.18 during Wednesday's after-market session. The market value of their outstanding shares is at $5.1 million. Oragenics (AMEX:OGEN) shares increased by 4.24% to $2.04. The market value of their outstanding shares is at $9.1 million. PACS Group (NYSE:PACS) shares rose 3.95% to $31.52. The market value of their outstanding shares is at $4.8 billion. MultiPlan (NYSE:MPLN) shares moved upwards by 3.49% to $0.45. The market value of their outstanding shares is at $290.3 million. Nanoviricides (AMEX:NNVC) stock moved upwards by 2.01% to $2.48. The market value of their outstanding shares is at $29.2 million. Calidi Biotherapeutics (AME
Shares of Lands’ End, Inc. (NASDAQ:LE) fell sharply during Wednesday's session following first-quarter results. Lands’ End reported quarterly adjusted loss of 20 cents per share which beat the analyst consensus estimate of 26 cents per share. The company reported quarterly sales of $285.47 million which beat the analyst consensus estimate of $269.82 million, according to data from Benzinga Pro. Lands’ End shares dipped 9.3% to $12.60 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Actelis Networks, Inc. (NASDAQ:ASNS) shares jumped 512% to $2.88 after the company announced orders for cyber-hardened networking technology to be deployed at thr
Gainers ENDRA Life Sciences (NASDAQ:NDRA) stock increased by 79.2% to $0.15 during Wednesday's regular session. The company's market cap stands at $1.6 million. Rezolute (NASDAQ:RZLT) stock moved upwards by 23.91% to $5.76. The company's market cap stands at $231.2 million. Bright Green (NASDAQ:BGXX) shares rose 23.07% to $0.36. The company's market cap stands at $69.0 million. Champions Oncology (NASDAQ:CSBR) shares increased by 22.42% to $5.65. The company's market cap stands at $76.8 million. Kineta (NASDAQ:KA) shares moved upwards by 22.11% to $0.53. The market value of their outstanding shares is at $6.4 million. CVRx (NASDAQ:CVRX) stock moved upwards by 21.57% to $7.89. The marke
Gainers ENDRA Life Sciences (NASDAQ:NDRA) stock increased by 71.6% to $0.15 during Wednesday's pre-market session. The company's market cap stands at $1.5 million. Concord Medical Services (NYSE:CCM) stock moved upwards by 29.04% to $2.71. The company's market cap stands at $117.6 million. Barinthus Biotherapeutics (NASDAQ:BRNS) shares increased by 21.69% to $2.3. The market value of their outstanding shares is at $89.7 million. Heart Test Laboratories (NASDAQ:HSCS) stock moved upwards by 12.87% to $5.81. The company's market cap stands at $3.8 million. I-MAB (NASDAQ:IMAB) shares increased by 12.23% to $2.11. The company's market cap stands at $170.6 million. Agenus (NASDAQ:AGEN) stock
Shares of Stitch Fix, Inc. (NASDAQ:SFIX) rose sharply in today's pre-market trading following better-than-expected third-quarter financial results. Stitch Fix reported quarterly losses of 18 cents per share which beat the analyst consensus estimate of losses of 24 cents by 25%. Quarterly sales came in at $322.7 million which beat the analyst consensus estimate of $306.121 million by 5.42% and represents a 18.29% decrease in sales from the same period last year, according to data from Benzinga Pro. Stitch Fix shares jumped 18% to $3.15 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers Actelis Networks, Inc. (NASDAQ:ASNS) rose 7
Gainers Concord Medical Services (NYSE:CCM) shares moved upwards by 131.0% to $4.85 during Tuesday's after-market session. The company's market cap stands at $210.6 million. Calidi Biotherapeutics (AMEX:CLDI) stock increased by 4.26% to $0.21. The market value of their outstanding shares is at $10.8 million. Anitra (AMEX:AZTR) shares moved upwards by 2.69% to $0.18. The market value of their outstanding shares is at $5.0 million. MAIA Biotechnology (AMEX:MAIA) stock rose 0.79% to $3.79. The company's market cap stands at $82.7 million. Emergent BioSolutions (NYSE:EBS) shares moved upwards by 0.53% to $5.59. The market value of their outstanding shares is at $292.9 million. Asensus Surg
Gainers Concord Medical Services (NYSE:CCM) shares moved upwards by 51.9% to $1.2 during Tuesday's regular session. The market value of their outstanding shares is at $52.1 million. Annexon (NASDAQ:ANNX) shares increased by 32.96% to $6.09. The company's market cap stands at $562.7 million. Olema Pharmaceuticals (NASDAQ:OLMA) stock moved upwards by 26.7% to $14.9. The company's market cap stands at $833.4 million. Pasithea Therapeutics (NASDAQ:KTTA) shares moved upwards by 22.59% to $7.0. The market value of their outstanding shares is at $7.3 million. Fresh2 Group (NASDAQ:FRES) stock moved upwards by 21.12% to $0.43. The company's market cap stands at $10.5 million. I-MAB (NASDAQ:IMAB
6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
20-F - Concord Medical Services Holdings Ltd (0001472072) (Filer)
6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
BEIJING, April 19, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 (the "Annual Report") with the U.S. Securities and Exchange Commission. An electronic copy of the Annual Report can be accessed on Concord Medical's investor relations website at http://ir.ccm.cn and on the SEC's website at www.sec.gov. Shareholders may receive a hard copy of the Annual Report free of charge upon request. Requests should be submitted to http://i
BEIJING, Feb. 20, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it has received a letter (the "Letter") from the New York Stock Exchange (the "NYSE") dated February 12, 2024, notifying the Company that it is below compliance standards due to the trading price of the Company's American depositary shares (the "ADSs") and that the applicable cure period for the Company to regain compliance expires on August 12, 2024. Pursuant to applicable NYSE continued listing standards, a company would be considered "below
BEIJING, Jan. 9, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced the listing of a minority stake of 39,420,200 H shares in Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), its subsidiary, at an initial public offer price of HK$14.28 per H share on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the stock code 2453.HK. Concord Healthcare's H shares began to trade on the HKSE on January 9, 2024. The Company previously announced the submission of an application proof to list a mi
BEIJING, Jan. 9, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced the listing of a minority stake of 39,420,200 H shares in Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), its subsidiary, at an initial public offer price of HK$14.28 per H share on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the stock code 2453.HK. Concord Healthcare's H shares began to trade on the HKSE on January 9, 2024. The Company previously announced the submission of an application proof to list a mi
BEIJING, Nov. 20, 2023 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced that it will hold its 2023 annual general meeting of shareholders (the "Meeting") on December 26, 2023, at 10:00 a.m. (Beijing Time). The meeting will be held at Room 26A1-26A5, East Tower, Hanwei Building, No. 7 Guanghua Road, Chaoyang District, Beijing, China. The shareholder record date is November 27, 2023. A copy
BEIJING, Sept. 22, 2023 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2023[1]. 2023 First Half Highlights Total net revenues were RMB284.5 million (US$39.2 million) in the first half of 2023, representing a 97.2% increase from total net revenues of RMB144.3 million in the same period last year. Total net rev
BEIJING, April 19, 2023 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2022 (the "Annual Report") with the U.S. Securities and Exchange Commission. An electronic copy of the Annual Report can be accessed on Concord Medical's investor relations website at http://ir.ccm.cn and on the SEC's website at www.se
BEIJING, Nov. 25, 2022 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced that it will hold its 2022 annual general meeting of shareholders (the "Meeting") on December 30, 2022, at 10:00 a.m. (Beijing Time). The meeting will be held at 27/F, Tower A, Global Trade Center, 36 North 3rd Ring Road East, Dongcheng District, Beijing, China. The shareholder record date is November 30, 2022. A copy
BEIJING, Nov. 16, 2022 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced the successful holding of the Second Annual Academic Meeting (the "Meeting") jointly by Shanghai Concord Cancer Center and The University of Texas MD Anderson Cancer Center ("MD Anderson") on November 11 and November 12, 2022. With the theme of "Immuno-Oncology: Confronting the Whole Cancer Continuum," the Meeting gath
BEIJING, Sept. 30, 2022 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced changes in its management. Mr. Yaw Kong Yap has stepped down from his role as the chief financial officer and president of the Company due to reaching retirement age, effective from September 30, 2022. Mr. Yap will continue to advise the Company going forward. Mr. Boxun Zhang, who previously served as an independent d